There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arrowhead Pharmaceuticals (ARWR – Research Report), Aclaris Therapeutics (ACRS – Research Report) and BellRing Brands (BRBR – Research Report) with bullish sentiments.
Arrowhead Pharmaceuticals (ARWR)
RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals today and set a price target of $77.00. The company’s shares closed last Tuesday at $32.32.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $59.44 average price target, representing a 77.2% upside. In a report released today, Robert W. Baird also maintained a Buy rating on the stock with a $58.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Aclaris Therapeutics (ACRS)
Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Aclaris Therapeutics today and set a price target of $38.00. The company’s shares closed last Tuesday at $13.63.
According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aclaris Therapeutics with a $34.80 average price target, implying a 150.2% upside from current levels. In a report issued on February 2, SVB Securities also reiterated a Buy rating on the stock.
BellRing Brands (BRBR)
Mizuho Securities analyst John Baumgartner reiterated a Buy rating on BellRing Brands today and set a price target of $38.00. The company’s shares closed last Tuesday at $30.89.
According to TipRanks.com, Baumgartner is a 4-star analyst with an average return of
Currently, the analyst consensus on BellRing Brands is a Strong Buy with an average price target of $31.60, implying a 7.7% upside from current levels. In a report issued on January 23, Needham also maintained a Buy rating on the stock with a price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARWR:
- Arrowhead initiates Phase 1/2a study of ARO-MMP7 to treat PF
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Arrowhead price target lowered to $60 from $82 at Chardan
- Arrowhead price target lowered to $55 from $64 at Piper Sandler
- Takeda Pharmaceutical, Arrowhead announce topline results from SEQUOIA study
